Zymeworks BC Inc [ZYME] stock is trading at $8.85, down -0.90%. An important factor to consider is whether the stock is rising or falling in short-term value. The ZYME shares have lost -2.64% over the last week, with a monthly amount drifted -17.37%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Neutral rating on January 04, 2023, and dropped its price target to $8. On December 20, 2022, upgrade upgraded it’s rating to Buy and revised its price target to $11 on the stock. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $8 on November 01, 2022. SVB Leerink downgraded its rating to a Mkt Perform but $8 remained the price target by the analyst firm on October 21, 2022. In a note dated May 05, 2022, Guggenheim upgraded an Buy rating on this stock but restated the target price of $14.
Zymeworks BC Inc [ZYME] stock has fluctuated between $6.01 and $13.14 over the past year. Currently, Wall Street analysts expect the stock to reach $9.5 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $8.85 at the most recent close of the market. An investor can expect a potential return of 7.34% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 76.01M for the trailing twelve months, which represents a drop of -95.79%. Gross Profit Margin for this corporation currently stands at -0.55% with Operating Profit Margin at -1.82%, Pretax Profit Margin comes in at -1.57%, and Net Profit Margin reading is -1.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.26 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.71 points at the first support level, and at 8.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.09, and for the 2nd resistance point, it is at 9.34.
Ratios To Look Out For
For context, Zymeworks BC Inc’s Current Ratio is 7.41. On the other hand, the Quick Ratio is 7.41, and the Cash Ratio is 2.83. Considering the valuation of this stock, the price to sales ratio is 8.29, the price to book ratio is 1.35.
Transactions by insiders
Recent insider trading involved Galbraith Kenneth, Chair & CEO, that happened on Jan 08 ’24 when 5706.0 shares were sold. Chief Scientific Officer, Moore Paul Andrew completed a deal on Jan 08 ’24 to sell 2339.0 shares. Meanwhile, SVP & Chief Financial Officer Astle Christopher sold 1431.0 shares on Jan 08 ’24.
